Assembly Biosciences (ASMB)

Healthcare · Biotechnology
$23.53 +3.11% on the day Market cap $327M 52-week range $21.80 to $39.71 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Assembly Biosciences's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

C

Five factors scored 1 to 9 from ASMB's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation6
Profitability0
Growth9
Financial health9
Cash efficiency0

Results from SEC filings

Fiscal years, from Assembly Biosciences's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$6M$0$7M$29M$72M
Net income-$130M-$93M-$61M-$40M-$6M
Free cash flow-$96M-$85M$22M-$51M-$41M
EPS (diluted)-$3.00-$23.08-$13.38-$6.69-$0.55
Operating margin-2121.7%—-902.5%-159.3%-16.8%

Superinvestors who own ASMB

From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Tom Steyer
Farallon Capital Management LLC
Added $44M0.20%Q2 2026

Insider buying

Open-market purchases by Assembly Biosciences's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.

No open-market insider purchases of ASMB in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when ASMB trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Assembly Biosciences insiders buying the stock?

No open-market insider purchases of ASMB in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Assembly Biosciences?

1 of the superinvestors Investingly tracks hold ASMB in their latest 13F, including Tom Steyer.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.